Factors affecting prescription of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus with established cardiovascular disease/ chronic kidney disease in Hong Kong: a qualitative study
Abstract Background Sodium-glucose co-transporter 2 inhibitors (SGLT2 I) has cardiorenal protective properties and are recommended for patients with diabetes and established atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Although cardiorenal complications are hig...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-12-01
|
Series: | BMC Primary Care |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12875-022-01928-z |